A5001135892- Transplantation: Methods and Outcomes
- RNA Interference and Gene Delivery
- Extracellular vesicles in disease
- MicroRNA in disease regulation
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Platelet Disorders and Treatments
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Organ Transplantation Techniques and Outcomes
- Polyomavirus and related diseases
- Cystic Fibrosis Research Advances
- Cancer-related molecular mechanisms research
- Renal Transplantation Outcomes and Treatments
Medical University of Vienna
2021-2024
Clinical evidence suggests an improvement or stabilization of lung function in a fraction patients with bronchiolitis obliterans syndrome (BOS) treated by extracorporeal photopheresis (ECP); however, few studies have explored the epigenetic and molecular regulation this therapy. The aim present study was to evaluate whether specific set miRNAs were significantly regulated ECP. Total RNA isolated from serum established BOS grade 1–2 prior start after 6 months ECP treatment. We observed...
Alemtuzumab is a monoclonal antibody targeting CD52, used as induction therapy after lung transplantation (LTx). Its engagement produces long-lasting immunodepletion; however, the mechanisms driving cell reconstitution are poorly defined. We hypothesized that miRNAs involved in this process. The expression of set miRNAs, cytokines and co-signaling molecules was measured with RT-qPCR flow cytometry prospectively collected serum samples LTx recipients, alemtuzumab or no therapy. Twenty-six...
Bronchiolitis obliterans syndrome (BOS) is the principal factor limiting long-term lung transplant survival. Available clinical evidence suggests improvement or stabilization of function in a fraction patients with BOS treated by extracorporeal photopheresis (ECP). However, few studies have explored epigenetic and molecular regulation this therapy. The aim present study was to evaluate underlying effects ECP analyze differential expression miRNAs potentially involved response patients. We...
Abstract Alemtuzumab is a monoclonal antibody targeting CD52, used as induction therapy after lung transplantation (LTx). Its engagement produces long-lasting immunodepletion; however, the mechanisms driving cell reconstitution are poorly defined. We hypothesized that miRNAs involved in this process. The expression of set miRNAs, cytokines and co-signaling molecules was measured with RT-qPCR flow cytometry prospectively collected serum samples LTx recipients, alemtuzumab or no therapy....